论文部分内容阅读
多年来,外科手术一直被认为是治愈肝细胞癌(HCC,简称肝癌)惟一的治疗方法,但HCC确诊后可以接受手术治疗的患者仅占10%～15%,且术后复发率高达40%～60%,近年来介入治疗成为不可切除中、晚期肝癌的主要治疗手段,并取得了良好疗效。随着HCC相关临床和基础研究深入发展,以及新技术、新材料、新理论的应用,使HCC介入治疗面临新的机遇和新的挑战。本文就HCC介入治疗的进展与现状作
Over the years, surgery has long been considered the only cure for hepatocellular carcinoma (HCC), but only 10% to 15% of patients who undergo surgery after HCC are diagnosed and have a recurrence rate of up to 40% ~ 60%, in recent years, interventional treatment has become the main treatment of unresectable, advanced liver cancer, and achieved good results. With the further development of HCC related clinical and basic research, as well as the application of new technologies, new materials and new theories, the interventional treatment of HCC faces new opportunities and new challenges. This article on the progress of HCC interventional treatment and status quo